Compuware Corporation (Nasdaq: CPWR), the technology performance company, is pleased to provide "day one" support for IBM's CICS Transaction Server for z/OS (CICS TS) V5.1, a crucial component of modern, multi-tiered and customer-facing applications. Compuware's CICS-supporting solutions--Abend-AID, Xpediter and Strobe--all work seamlessly with the new release of CICS TS to provide essential support for building, debugging and improving the performance of CICS workloads.
"We know that many of our customers rely on CICS TS to run their business-critical applications," said Kris Manery, Senior Vice President and General Manager, Mainframe Solutions Business Unit, Compuware. "It's imperative they make a smooth migration to the new server, which is why we've invested time and resources to ensure that Abend-AID, Xpediter and Strobe are fully compatible with the new release. Our customers can relax knowing our solutions will be fully operational once the transition to the new software has occurred."
Effective on January 7, 2013, Jeff Ross will take over as the Chief Financial Officer for Velti (NASDAQ: VELT). Ross has more than 25 years of experience in international finance and will join as the fourth senior executive to join Velti in the past six months.
Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial.
Jefferies noted, “CLDX presented positive CDX-011 OS data for TNBC+hGPNMB pts in EMERGE with supportive PFS data, potentially enabling a follow-on accelerated PII trial. Encouraging OS data for hGPNMB only also support a favorable long-term outlook in a broader pt population. With the rindo PIII ongoing and a pot'l pivotal CDX-011 prgm in 6-12 mos (pipeline as upside), CLDX is an attractive small-cap biotech play. Reiterate Buy with a new $9 PT.”
Badger Meter (NYSE: BMI) Reported Q3 EPS $0.62 May Not Compare to $0.47 Est; Revenues $87.1MN vs $80.02M Est at 4:12pm EST on October 16, 2012.
On October 17, 2012, BMI opened 15.07% higher than the previous day's close.